AI Science Tracker

MolE prioritizes existing drugs with measured Staphylococcus aureus growth effects

University of Tübingen · 11 Mar 2024 · biology

Discovery

MolE prioritizes existing drugs with measured Staphylococcus aureus growth effects

MolE-XGBoost prioritized existing compounds. Of six tested commercially available compounds, elvitegravir, opicapone and ebastine showed measured growth-inhibitory effects on S. aureus; visomitin was a known-antimicrobial positive control. Effects varied: elvitegravir inhibited growth at 8 μg/mL, while the other two limited or delayed growth. This is an in-vitro finding, not a clinical antibiotic.

Technology: MolE molecular representation learning; XGBoost

Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Preprint
  • Test type: direct test
  • Tested: The primary source reports the study-specific result summarized here.
  • Still unknown: Independent replication and broad deployment are not established by this review.
  • AI role: A learned molecular representation and XGBoost rank candidates for experimental screening; selected compounds undergo MIC and growth-curve assays.

Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11986102/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 16 Nov 2026. Review scope: Primary-source indexed article or abstract and bibliographic metadata reviewed; complete source scope is given in source_checks..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open in the full catalog for filters, charts and related discoveries.